Pharmaceutical News

RSS

Parenteral Biotech to supply and distribute Sinovac Biotech's Anflu and PANFLU.1 vaccines in India

Sinovac Biotech Ltd., a leading China-based vaccine manufacturer, announced today it has entered into exclusive license, supply and distribution agreements with Parenteral Biotech Ltd., a subsidiary of Parenteral Drugs (India), Ltd., an India-based pharmaceutical company. Pursuant to the agreements, Parenteral is authorized to register, supply and distribute Sinovac's Anflu (seasonal influenza vaccine) and PANFLU.1 (H1N1 vaccine) to the government of India and private market in India. Currently, the registration process is ongoing in India.

29 Mar 2010

PROCAPS granted exclusive rights to commercialize Pro-Pharmaceuticals' DAVANAT in Colombia

Pro-Pharmaceuticals, Inc., a developer of therapeutics that target Galectin receptors to treat cancer and fibrosis, today announced that it has granted PROCAPS S.A. exclusive rights to market and sell DAVANAT® to treat cancer in Colombia, South America. Phase ll clinical trial results for late-stage colorectal cancer patients demonstrate that when DAVANAT® is co-administered with the chemotherapy drug 5-FU, survival increased by 46% over the best standard of care and reduced serious adverse events associated with chemotherapy.

29 Mar 2010

Redpoint Bio announces revenue of $1.9M for full-year 2009

Redpoint Bio Corporation, a company focused on the development of healthier foods and beverages and new approaches to the treatment of diabetes and obesity, today announced financial and operational results for the quarter and year ended December 31, 2009.

29 Mar 2010

Naturalhealthylife.co.uk celebrates National Garlic Day

Naturalhealthylife.co.uk, the official UK site for herbal supplements made by Klosterfrau, are celebrating National Garlic Day on Monday 19th April. Klosterfrau is a leading manufacturer of herbal healthcare products.

29 Mar 2010

Erbitux can now be used in Japan as 1st-line treatment for mCRC: Merck Serono

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced today that Erbitux® (cetuximab) can now be used in Japan in combination with chemotherapy in the 1st-line treatment for patients with epidermal growth factor receptor -expressing, curatively unresectable (inoperable), advanced or recurrent colorectal cancer carrying the KRAS wildtype gene.

29 Mar 2010

Scientists link gene expression profiling effort to identify potential novel therapeutic for ALS

In an article published in Nature Genetics today, scientists at the ALS Therapy Development Institute describe how they have linked an unbiased gene expression profiling effort to the identification and successful preclinical testing of a potential novel therapeutic for amyotrophic lateral sclerosis.

29 Mar 2010

Cortex signs agreement to sell certain AMPAKINE compounds to Biovail

Cortex Pharmaceuticals, Inc. announced that it has entered into an agreement with Biovail Laboratories International SRL in which Biovail acquired certain AMPAKINE compounds and the rights to the patent filing for respiratory depression and vaso-occlusive crises associated with sickle cell disease.

29 Mar 2010

New data on EHT 0202 for treatment of patients with AD presented at Geneva/Springfield Symposium

ExonHit Therapeutics announced today that promising new data on EHT 0202, its lead candidate in Alzheimer's disease, were presented at the 11th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy from March 24th to March 27th in Geneva, Switzerland.

29 Mar 2010

Two-drug combination destroys precancerous colon polyps

A two-drug combination destroys precancerous colon polyps with no effect on normal tissue, opening a new potential avenue for chemoprevention of colon cancer, a team of scientists at The University of Texas M. D. Anderson Cancer Center reports in the advance online edition of the journal Nature.

29 Mar 2010

CVS/pharmacy to help consumers dispose unwanted medication in an effort to protect the environment

CVS/pharmacy announced today that it will collect expired or unused medications from the public at two collection events in Rhode Island to be held at stores in the town of Coventry and the city of Cranston in April.

27 Mar 2010

DSA to discuss challenges in drug development at Late Phase Drug Development World 2010

Drug Safety Alliance, a global leader in drug safety and pharmacovigilance, announced that Dr. Elizabeth Garrard, PharmD, RPh, would participate in “Late Phase Drug Development World 2010,” a first of its kind strategic forum addressing challenges in drug development.

27 Mar 2010

WinRho SDF for ITP: Cangene announces new safety information

Cangene Corporation, in consultation with Health Canada, is informing Canadian patients and healthcare professionals of important new safety information concerning the use of WinRho SDF (Rho (D) Immune Globulin (Human)) for the treatment of immune thrombocytopenic purpura, also called immune thrombocytopenia, or ITP. WinRho SDF belongs to a group of biological medicines derived from human plasma known as immunoglobulins. It is administered in hospitals by infusion through the veins.

27 Mar 2010

Two EMBEDA video news releases misleading, warns FDA DDMAC

On October 8, 2009, King Pharmaceuticals, Inc. received a Warning Letter from the Division of Drug Marketing, Advertising, and Communications (DDMAC) at the Food and Drug Administration regarding two video news releases - EMBEDA Media backgrounder, and EMBEDA Visual Media Technology, for EMBEDA® (morphine sulfate and naltrexone hydrochloride) Extended Release Capsules for oral use C-II.

27 Mar 2010

FDA approves Graceway Pharmaceuticals' NDA for Zyclara

Graceway® Pharmaceuticals announced today that the Food and Drug Administration has approved the New Drug Application for Zyclara™, determining it to be safe and effective for the treatment of clinically typical, visible or palpable actinic keratoses.

27 Mar 2010

Health Canada accepts Cipher Pharmaceuticals' NDS for CIP-TRAMADOL ER

Cipher Pharmaceuticals Inc. today announced that its New Drug Submission (NDS) to Health Canada for CIP-TRAMADOL ER, its extended-release formulation of tramadol, has been accepted for review. The Company expects the review to be completed by early 2011.

26 Mar 2010

ARCA biopharma granted patent for methods of treating heart failure patients with bucindolol based on genetic testing

ARCA biopharma, Inc., a biopharmaceutical company developing genetically targeted therapies for heart failure and other cardiovascular diseases, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a patent on methods of treating heart failure patients with bucindolol based on genetic testing.

26 Mar 2010

Invida to continue commercialization of Actelion's Tracleer for PAH in crucial Asian markets

Invida Group, the leading provider of healthcare brands and services to the Asia Pacific region, today announced that its contract with Swiss biotechnology company, Actelion, has been extended through 2015 to continue commercialization of Tracleer® for the treatment of pulmonary arterial hypertension (PAH) in crucial markets throughout Asia. Actelion signed with Invida initially in 2005, and has extended the contract to market the company’s lead product, Tracleer, in Thailand, Malaysia, Philippines, Vietnam, and Hong Kong

26 Mar 2010

Anxiety may rise again, says Rutgers University dean

Poet W.H Auden dubbed the post-World War II nuclear era the "age of anxiety" and indeed, at the time, anxiety disorders were the most commonly diagnosed mental illnesses. Yet, by the 1990s, American psychiatry was "Listening to Prozac" and instead of obsessing about angst, it focused its attention on depression.

26 Mar 2010

Collegium Pharmaceutical files IND for second opioid product using DETERx technology

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, today announced that it has filed an Investigational New Drug application for COL-172, a tamper-resistant, extended-release oral opioid formulation intended to treat moderate to severe pain in individuals who require around-the-clock opioid therapy for an extended period of time.

26 Mar 2010

ADVENTRX Pharmaceuticals to meet FDA to review its NDA for ANX-530

ADVENTRX Pharmaceuticals, Inc. today announced that it will meet the U.S. Food and Drug Administration in Washington D.C. during the last week of April 2010 to review the Company's New Drug Application for ANX-530 (vinorelbine injectable emulsion) and the FDA's refusal-to-file letter.

26 Mar 2010

Pharmaceutical News

Parenteral Biotech to supply and distribute Sinovac Biotech's Anflu and PANFLU.1 vaccines in India

PROCAPS granted exclusive rights to commercialize Pro-Pharmaceuticals' DAVANAT in Colombia

Redpoint Bio announces revenue of $1.9M for full-year 2009

Naturalhealthylife.co.uk celebrates National Garlic Day

Erbitux can now be used in Japan as 1st-line treatment for mCRC: Merck Serono

Scientists link gene expression profiling effort to identify potential novel therapeutic for ALS

Cortex signs agreement to sell certain AMPAKINE compounds to Biovail

New data on EHT 0202 for treatment of patients with AD presented at Geneva/Springfield Symposium

Two-drug combination destroys precancerous colon polyps

CVS/pharmacy to help consumers dispose unwanted medication in an effort to protect the environment

DSA to discuss challenges in drug development at Late Phase Drug Development World 2010

WinRho SDF for ITP: Cangene announces new safety information

Two EMBEDA video news releases misleading, warns FDA DDMAC

FDA approves Graceway Pharmaceuticals' NDA for Zyclara

Health Canada accepts Cipher Pharmaceuticals' NDS for CIP-TRAMADOL ER

ARCA biopharma granted patent for methods of treating heart failure patients with bucindolol based on genetic testing

Invida to continue commercialization of Actelion's Tracleer for PAH in crucial Asian markets

Anxiety may rise again, says Rutgers University dean

Collegium Pharmaceutical files IND for second opioid product using DETERx technology

ADVENTRX Pharmaceuticals to meet FDA to review its NDA for ANX-530

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News